Cargando…
DYRK1A suppression attenuates HIF-1α accumulation and enhances the anti-liver cancer effects of regorafenib and sorafenib under hypoxic conditions
Hypoxia promotes drug resistance and induces the expression of hypoxia inducible factor (HIF)-1α in liver cancer cells. However, to date, no selective HIF-1α inhibitor has been clinically approved. The aim of this study is to investigate a drug-targetable molecule that can regulate HIF-1α under hypo...
Autores principales: | Zhang, Chong, Wu, Lin-Wen, Li, Zhi-Di, Zhang, Man-Man, Wu, Jie, Du, Fei-Hua, Zeng, Ling-Hui, Li, Yang-Ling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923653/ https://www.ncbi.nlm.nih.gov/pubmed/35244188 http://dx.doi.org/10.3892/ijo.2022.5335 |
Ejemplares similares
-
DYRK1A reinforces epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma via cooperatively activating STAT3 and SMAD
por: Li, Yang-ling, et al.
Publicado: (2022) -
Inhibition of the PINK1-Parkin Pathway Enhances the Lethality of Sorafenib and Regorafenib in Hepatocellular Carcinoma
por: Zhang, Shun, et al.
Publicado: (2022) -
Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF‐1α/SLC7A11 pathway
por: Yuan, Siyu, et al.
Publicado: (2021) -
DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
por: Li, Yangling, et al.
Publicado: (2020) -
Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
por: Li, Yangling, et al.
Publicado: (2022)